Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 18INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Melanoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Thymalfasin × Clear all
NCT02906150 2016-09-19

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

SciClone Pharmaceuticals

Phase 2 Unknown
140 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

SciClone Pharmaceuticals

Phase 1/2 Unknown
188 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00911443 2009-07-09

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

sigma-tau i.f.r. S.p.A.

Phase 2 Completed
488 enrolled 12 charts
Dermatologic

Melanoma

NCT00082082 2008-01-15

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

SciClone Pharmaceuticals

Phase 2 Completed
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡